Health

U.S. FDA Grants Approval for Jivi (Antihemophilic Factor (Recombinant), PEGylated-aucl) in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A

DailyTrendDailyTrend
May 23, 2025 - 19:00
 0  0
U.S. FDA Grants Approval for Jivi (Antihemophilic Factor (Recombinant), PEGylated-aucl) in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A
WHIPPANY, N.J.--(BUSINESS WIRE) May 19, 2025 --Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII concentrate, for use in pediatric patients 7 years of age...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

The Madden Sisters Don’t Want to Be Institutionalized

The Madden Sisters Don’t Want to Be Institutionalized

DailyTrend Aug 18, 2025  0  0

Congo Has Astronomical Rates of Sexual Violence. Now Vi...

DailyTrend Aug 22, 2025  0  0

B. Braun Medical Issues Voluntary Nationwide Recall of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL Due to the Presence of Particulate Matter

B. Braun Medical Issues Voluntary Nationwide Recall of ...

DailyTrend Aug 20, 2025  0  0

Wegovy Granted Accelerated Approval in the US for the Treatment of MASH

Wegovy Granted Accelerated Approval in the US for the T...

DailyTrend Aug 18, 2025  0  0

A New Way to Reduce Children’s Deaths: Cash

A New Way to Reduce Children’s Deaths: Cash

DailyTrend Aug 18, 2025  0  0

Was Head-Binding an Ancient Way to Get Ahead?

DailyTrend Aug 22, 2025  0  0